PEGylated Proteins Market by Protein Type, Application, End-Users, and Region – Global Market Size Estimation, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2029
Overview
PEGylated Proteins Market is expected to reach US$ 2.50 Bn. at a CAGR of 10.45% during the forecast period 2029.
PEGylated Proteins Market Overview:
PEGylation is the process of attaching polyethylene glycol polymer chains to molecules, such as a medication, therapeutic protein, or vesicle, using covalent and non-covalent means. By changing the electrostatic binding, confirmation, and hydrophobicity of the molecule, PEGylation promotes medicine stability and solubility while lowering immunogenicity.
To know about the Research Methodology :- Request Free Sample Report
PEGylated Proteins Market Dynamics:
Rising prevalence of lifestyle diseases is the major factor driving the market growth.
The market is expected to grow due to the growing biologics industry, increased acceptance of protein-based medications over non-protein-based medications, and the increasing prevalence rate of lifestyle diseases. The rising frequency of chronic diseases such as cancer, kidney disease, and rheumatoid arthritis are driving the growth of the PEGylated protein therapies market. According to the Centres for Disease Control and Prevention's Chronic Kidney Disease in the United States, 2021 study, chronic kidney disease affects 15% of American adults, or 37 million people. These days, research into the creation of new therapies based on PEGylated proteins for the treatment of chronic renal disease is quite important. Protein-based medications are increasingly being preferred over non-protein-based medications because PEGylation improves protein circulation and half-life, therefore improving efficacy.
The market's growth is also fuelled by a wide range of applications and increased protein stability. In the forecast, top-selling biologics medications coming off-patent will generate growth prospects for the PEGylated proteins industry. On the other hand, rising PEGylation process costs and the patent expiration of certain medications are expected to hamper market growth.
The report has profiled sixteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.
PEGylated Proteins Market Segment Analysis:
The Global PEGylated Proteins Market is segmented on the basis of Protein Type, Application and End-Users.
Based on Protein Type, the Colony Stimulating Factors segment is expected to grow at a higher CAGR of xx% during the forecast period. Colony-stimulating factors are compounds that speed up the creation of blood cells while also improving their functionality. They don't directly affect tumours, but they can have a function in activating blood cells, so they can help maintain a person's immune system throughout cancer treatment. The increasing incidence of cancer around the world, as well as the use of peptide treatment for cancer, is driving the segment's growth. According to Globocan, the global cancer incidence in 2022 is expected to be 19,292,789 cases, with almost 9,958,133 cancer-related deaths. Furthermore, increased patient and healthcare professional awareness of the negative consequences of existing cancer treatments, such as chemotherapy and radiation therapy, is a major reason for the growing interest in alternative medicines such as PEGylated peptide-based medications.
Based on Application, the Cancer segment is expected to hold a dominant market share xx% by 2029. The segment growth is attributed to the rising number of cancer-infected patients around the world. According to the World Health Organization, cancer is the second biggest cause of mortality, accounting for 9.6 million deaths worldwide in 2022, or one in every six deaths. Poly(ethylene glycol) (PEG)-based advanced drug delivery systems are a significant advancement in anti-cancer therapy. PEGylation can increase the retention period of treatments such as proteins, enzymes, tiny molecular medicines, liposomes, and nanoparticles by shielding them from numerous degrading mechanisms that occur inside a tissue or cell, hence improving their therapeutic efficacy.
PEGylated Proteins Market Regional Insights:
North America is expected to dominate the global market throughout the forecast period.
Throughout the projected period, North America is likely to dominate the global PEGylated protein market. The presence of prominent competitors, the high prevalence of chronic diseases in the region established healthcare infrastructure, and growing knowledge of modern treatment choices among the American population are some of the important factors driving the market's growth. Furthermore, the growing the elderly population and the increasing prevalence of chronic diseases are likely to contribute significantly to the market's growth. Growing demand for biologics medications such as erythropoietin, monoclonal antibodies, and interferon for treating chronic illnesses, as well as substantial government financing and grants for research activities are some of the major growth drivers in the region.
The report also helps in understanding Global PEGylated Proteins Market dynamics, structure by analyzing the market segments and project the Global PEGylated Proteins Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global PEGylated Proteins Market make the report investor’s guide.
PEGylated Proteins Market Scope: Inquire before buying
| PEGylated Proteins Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2022 | Forecast Period: | 2023-2029 |
| Historical Data: | 2017 to 2022 | Market Size in 2022: | US $ 1.24 Bn. |
| Forecast Period 2023 to 2029 CAGR: | 10.45% | Market Size in 2029: | US $ 2.50 Bn. |
| Segments Covered: | by Protein Type | • Colony-stimulating Factors • Interferons • Erythropoietin • Other Protein Types |
|
| by Application | • Cancer • Autoimmune Disease • Multiple Sclerosis • Hemophilia • Gastrointestinal Disorder |
||
| by End-Users | • Pharmaceutical and Biotechnology Companies • Contract Research Organizations • Academic Research Institutes |
||
PEGylated Proteins Market, by Region
• North America (United States, Canada and Mexico)
• Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
• Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
• Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
• South America (Brazil, Argentina Rest of South America)
PEGylated Proteins Market Key player
• Merck KGaA
• Thermo Fisher Scientific Inc.
• NOF America Corporation
• JenKem Technology USA
• Creative PEGWorks
• celares GmbH
• QUANTA BIODESIGN, LTD.
• Biomatrik Inc.
• IRIS BIOTECH GMBH
• Laysan Bio, Inc.
• Valley Proteins, Inc.
• Therapeutic Proteins International, LLC
• Enzon Pharamaceuticals, Inc
• Takeda Pharmaceuticals Company Limited
• F. Hoffmann-La Roche Ltd.
• Horizon Pharma plc.
Frequently Asked Questions:
1. Which region has the largest share in Global PEGylated Proteins Market?
Ans: North America region held the highest share in 2022.
2. What is the growth rate of Global PEGylated Proteins Market?
Ans: The Global PEGylated Proteins Market is expected to grow at a CAGR of 10.45% during forecast period 2023-2029.
3. What is scope of the Global PEGylated Proteins market report?
Ans: Global PEGylated Proteins Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global PEGylated Proteins market?
Ans: The important key players in the Global PEGylated Proteins Market are – , Merck KGaA, Thermo Fisher Scientific Inc., NOF America Corporation, JenKem Technology USA, Creative PEGWorks, celares GmbH, QUANTA BIODESIGN, LTD., Biomatrik Inc., IRIS BIOTECH GMBH, Laysan Bio, Inc., Valley Proteins, Inc., Therapeutic Proteins International, LLC, Enzon Pharamaceuticals, Inc, Takeda Pharmaceuticals Company Limited, F. Hoffmann-La Roche Ltd., and Horizon Pharma plc.
5. What is the study period of this market?
Ans: The Global PEGylated Proteins Market is studied from 2022 to 2029.